The Tension Between Cost Containment and the Underutilization of Effective Health Services

One of the common ingredients in all attempts to slow escalating health care costs is to control the utilization of services that provide little or uncertain benefit. To reform existing delivery systems, the organization, provision, and financing of health care need to be evaluated critically. Successful reform requires that more rational methods be used to determine which services to provide. The preferences of physicians, patients, and payers of care do not appear optimal from a societal perspective in choosing health care services. While reducing the use of interventions of little or unknown benefit should save money, a policy to restrict the use of medical services may lead to an unwanted result: the underutilization of interventions of proven clinical benefit. Through the determination of the value--by rigorous assessment of both costs and benefits of available alternatives--in a context sensitive to the unique cultural, political, and economic characteristics of individual nations, the health of the population should be improved and growth of health expenditures constrained. This is the first step in health care reform.

[1]  T. Jefferson,et al.  Is vaccination against hepatitis B efficient? A review of world literature. , 1994, Health economics.

[2]  R A Rettig,et al.  Medical innovation duels cost containment. , 1994, Health affairs.

[3]  Dennis G. Fryback,et al.  Cost-Effectiveness of Strategies for Detecting Diabetic Retinopathy , 1991, Medical care.

[4]  A S Kapadia,et al.  Cost-Effectiveness of Alternative Methods for Diabetic Retinopathy Screening , 1992, Diabetes Care.

[5]  D. Grimes,et al.  Technology follies. The uncritical acceptance of medical innovation. , 1993, JAMA.

[6]  L. Greenwald,et al.  Health spending, delivery, and outcomes in OECD countries. , 1993, Health affairs.

[7]  B. Bloom,et al.  Improved health benefits of increased use of thrombolytic therapy. , 1994, Archives of internal medicine.

[8]  E. Topol,et al.  Thrombolytic therapy of acute myocardial infarction. Keeping the unfulfilled promises. , 1992, JAMA.

[9]  G. de Pouvourville,et al.  Treatment of Symptomatic Cholelithiasis in France: A Decision Analysis Comparing Cholecystectomy and Biliary Lithotripsy , 1992, International Journal of Technology Assessment in Health Care.

[10]  A. Detsky,et al.  Should Canada and the United States Universally Vaccinate Infants against Hepatitis B? , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[11]  R. Beasley Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.

[12]  Keith A. Soper,et al.  Diagnosis of diabetic eye disease. , 1982, JAMA.

[13]  B. Bloom,et al.  A Reappraisal of Hepatitis B Virus Vaccination Strategies Using Cost-Effectiveness Analysis , 1993, Annals of Internal Medicine.

[14]  A. L. Cochrane,et al.  Effectiveness and efficiency: random reflections on health services , 1972 .

[15]  J C Javitt,et al.  Cost effectiveness of current approaches to the control of retinopathy in type I diabetics. , 1989, Ophthalmology.

[16]  T R Fleming,et al.  An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. , 1993, JAMA.

[17]  F. Ferris,et al.  How effective are treatments for diabetic retinopathy? , 1993, JAMA.